Logo-ps
Pharm Sci. 2020;26(3): 287-295. doi: 10.34172/PS.2020.33

Research Article

Protective Effects of Silymarin on Gentamicin-Induced Nephrotoxicity in Infectious Patients: A Randomized Double Blinded Placebo-Controlled Clinical Trial

Motahareh Mahi-birjand 1,2 ORCID, Iman Karimzadeh 3, Asghar Zarban 4, Meghdad Abdollahpour-Alitappeh 5 ORCID, Seyed Alireza Saadatjoo 6, Masood Ziaee 1 * ORCID

Cited by CrossRef: 6


1- Ghiasian M, Nafisi H, Ranjbar A, Mohammadi Y, Ataei S. Antioxidative effects of silymarin on the reduction of liver complications of fingolimod in patients with relapsing–remitting multiple sclerosis: A clinical trial study. J Biochem & Molecular Tox. 2021;35(8) [Crossref]
2- Aryan H, Farahani R, Chamanara M, Elyasi S, Jaafari M, Haddad M, Sani A, Ardalan M, Mosaed R. Evaluation of the efficacy of oral nano‐silymarin formulation in hospitalized patients with COVID‐19: A double‐blind placebo‐controlled clinical trial. Phytotherapy Research. 2022;36(10):3924 [Crossref]
3- Erfanian S, Ansari H, Javanmard S, Amini Z, Hajigholami A. The hepatorenal protective effects of silymarin in cancer patients receiving chemotherapy: a randomized, placebo-controlled trial. BMC Complement Med Ther. 2024;24(1) [Crossref]
4- Bahari H, Shahraki Jazinaki M, Rashidmayvan M, Taheri S, Amini M, Malekahmadi M. The effects of silymarin consumption on inflammation and oxidative stress in adults: a systematic review and meta-analysis. Inflammopharmacol. 2024;32(2):949 [Crossref]
5- Hormozi M, Ahmadvand H, Tavafi M, Baharvand P. Effectiveness of setarud (IMOD™) in attenuating gentamicin-induced nephrotoxicity in male rats. Discov Appl Sci. 2024;6(7) [Crossref]
6- Karimian A, Karimzadeh I, Shafiekhani M, Heidari R, Masjedi F, Izadi F, Barshan-Tashnizi N, Kane-Gill S, Mahmoudi L. Protective effects of silymarin on preventing vancomycin nephrotoxicity in infectious patients: a randomized, double-blinded, placebo-controlled, pilot clinical trial. Naunyn-Schmiedeberg's Arch Pharmacol. 2024; [Crossref]